Company Description
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally.
Its lead drug candidate is Fexapotide Triflutate (NX-1207), which is in various clinical trials for the treatment of benign prostatic hyperplasia and low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma.
The company also develops and markets NicAlert for detecting tobacco product usage; and TobacAlert for detecting second-hand smoke exposure.
In addition, it develops drugs for the treatment of Alzheimer's disease. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Nassau, the Bahamas.
| Country | Quebec, Canada |
| Founded | 1989 |
| IPO Date | Dec 1, 1997 |
| Industry | Biotechnology |
| Sector | Healthcare |
Contact Details
Address: 9900 Cavendish Blvd., Suite 306, St. Laurent Quebec Canada, A8 H4M 2V2 Quebec, Canada | |
| Phone | 1-800-936-9669 |
Stock Details
| Ticker Symbol | NYMXF |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001018735 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Dr. Paul Averback DABP, M.D. | Founder, Chairman, Chief Executive Officer and President |
| Lin Dodd | QA and Compliance Manager |
| Patrick Doody | Vice President, General Counsel and Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 28, 2024 | 6-K | Report of foreign issuer |
| Nov 15, 2023 | 6-K | Report of foreign issuer |
| Nov 9, 2023 | 6-K | Report of foreign issuer |
| Nov 6, 2023 | 6-K | Report of foreign issuer |
| Oct 26, 2023 | 6-K | Report of foreign issuer |
| Sep 25, 2023 | 6-K | Report of foreign issuer |
| Sep 8, 2023 | 25-NSE | Filing |
| Aug 29, 2023 | 6-K | Report of foreign issuer |
| Aug 14, 2023 | 6-K | Report of foreign issuer |
| Aug 2, 2023 | 6-K | Report of foreign issuer |